Tonix Pharmaceuticals stock halted ahead of FDA approval news
Franco-Nevada Corporation’s stock reached a new all-time high of 180.15 USD, showcasing a significant milestone for the company. According to InvestingPro data, the company maintains impressive gross profit margins of nearly 90% and boasts a robust market capitalization of $34.6 billion. Over the past year, Franco-Nevada has experienced a remarkable 53.82% increase in its stock value, with a particularly strong year-to-date return of 52%, reflecting strong investor confidence and positive market performance. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with analysts setting price targets ranging from $182 to $210. This all-time high underscores Franco-Nevada’s robust financial health, evidenced by its "GOOD" Financial Health score from InvestingPro, and the successful execution of its business strategies, positioning it favorably within the commodities and mining sector. The company’s continued growth trajectory highlights its resilience and adaptability in a fluctuating market environment, supported by its 17-year track record of consecutive dividend increases and strong liquidity position with current ratio of 4.25.Want deeper insights? InvestingPro offers 14 additional investment tips and a comprehensive Pro Research Report for Franco-Nevada, helping investors make more informed decisions about this dividend aristocrat.
In other recent news, Franco-Nevada Corporation reported its Q2 2025 earnings, achieving an earnings per share (EPS) of $1.28, which exceeded analyst forecasts of $1.13. However, the company’s revenue was slightly below expectations, totaling $369.4 million compared to the anticipated $375.91 million. In related developments, Scotiabank adjusted its price target for Franco-Nevada to $184 from $182, while maintaining a Sector Perform rating on the stock. This adjustment coincides with Franco-Nevada’s ongoing collaboration with First Quantum and the Government of Panama concerning the potential restart of the Cobre Panama mine. The discussions include the sale of concentrate on site. These recent developments are crucial for investors keeping an eye on Franco-Nevada’s performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.